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RESEARCH ARTICLE
Prevalence and trends in transmitted 
and acquired antiretroviral drug resistance, 
Washington, DC, 1999–2014
Annette M. Aldous1, Amanda D. Castel1, David M. Parenti2* and the DC Cohort Executive Committee
Abstract 
Background: Drug resistance limits options for antiretroviral therapy (ART) and results in poorer health outcomes 
among HIV-infected persons. We sought to characterize resistance patterns and to identify predictors of resistance in 
Washington, DC.
Methods: We analyzed resistance in the DC Cohort, a longitudinal study of HIV-infected persons in care in Washing-
ton, DC. We measured cumulative drug resistance (CDR) among participants with any genotype between 1999 and 
2014 (n = 3411), transmitted drug resistance (TDR) in ART-naïve persons (n = 1503), and acquired drug resistance 
(ADR) in persons with genotypes before and after ART initiation (n = 309). Using logistic regression, we assessed asso-
ciations between patient characteristics and transmitted resistance to any antiretroviral.
Results: Prevalence of TDR was 20.5%, of ADR 40.5%, and of CDR 45.1% in the respective analysis groups. From 2004 
to 2013, TDR prevalence decreased for nucleoside and nucleotide analogue reverse transcriptase inhibitors (15.0 to 
5.5%; p = 0.0003) and increased for integrase strand transfer inhibitors (INSTIs) (0.0–1.4%; p = 0.04). In multivariable 
analysis, TDR was not associated with age, race/ethnicity, HIV risk group, or years from HIV diagnosis.
Conclusions: In this urban cohort of HIV-infected persons, almost half of participants tested had evidence of CDR; 
and resistance to INSTIs was increasing. If this trend continues, inclusion of the integrase-encoding region in baseline 
genotype testing should be strongly considered.
Keywords: HIV, Antiretroviral therapy, Drug resistance, Transmitted drug resistance, Acquired drug resistance, 
Cumulative drug resistance, Prevalence, Washington, DC
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Background
Since 1995, the use of combination antiretroviral therapy 
(ART) has dramatically improved life expectancy and 
health outcomes for people infected with HIV, but resist-
ance to antiretroviral drugs (ARVs) undermines their 
effectiveness [1–4]. Drug resistance may be acquired in 
response to drug pressure (ADR) or transmitted at the 
time of infection (TDR). In the United States (US), esti-
mates of TDR prevalence range from 4 to 27% [5–28]. 
Some reports indicate that resistance to nucleoside and 
nucleotide analogue reverse transcriptase inhibitors 
(NRTIs) has remained stable or decreased, while resist-
ance to nonnucleoside reverse transcriptase inhibitors 
(NNRTIs) and protease inhibitors (PIs) has remained sta-
ble or increased [14, 19, 23, 26–28]. Few data are avail-
able on the prevalence of resistance to the newer ARV 
classes: entry/fusion inhibitors (EIs) and integrase strand 
transfer inhibitors (INSTIs). Two recent studies found no 
resistance to INSTIs [29, 30]; however, with INSTI-based 
regimens featuring prominently in the latest US Depart-
ment of Health and Human Services treatment guidelines 
[31], increasing resistance to this class is likely.
While TDR has been fairly well documented, fewer 
data exist on rates of ADR and of cumulative drug resist-
ance (CDR), a term we use to encompass all resistance, 
whether transmitted, acquired, or of unknown origin. 
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One study of homeless persons in San Francisco found 
ADR prevalence of 36% [9]. The same study and one 
other found CDR prevalence rates of 27 and 45%, respec-
tively [9, 32]. These categories of resistance may provide 
an indication of how well a city is maintaining treatment 
and adherence in its infected population. Additionally, 
Tilghman et al. found that high levels of CDR at specific 
gene locations predicted TDR in the same locations [33].
In Washington, DC, which has an HIV prevalence of 
2.5% [34], recent studies of TDR have found that 17–23% 
of participants had mutations associated with resist-
ance to at least one drug [26, 28] while two earlier stud-
ies reported resistance rates of up to 17%, depending 
on drug class [35, 36]. These findings suggest resistance 
is common, yet citywide prevalence is unknown. The 
DC Cohort, a longitudinal observational study of HIV-
infected persons receiving outpatient care at 13 clin-
ics throughout Washington, DC [37], affords a unique 
opportunity to characterize prevalence in a major urban 
area with a high burden of HIV. With 6743 people 
enrolled as of December 2014, including 4969 DC resi-
dents, the study aims to provide a representative sam-
ple of the 16,423 people estimated to be living with HIV 
in the city [34]. Additionally, the longitudinal nature 
of the study makes it possible to distinguish, for some 
participants, between transmitted and acquired drug 
resistance.
In this analysis, we aimed to describe the prevalence 
of and trends in ARV drug resistance among DC Cohort 
participants by category of resistance (TDR, ADR, and 
CDR); specifically, to measure prevalence of individual 
drug resistant mutations and to estimate resistance to 
individual drugs and drug classes. We further sought to 
examine associations between patient characteristics and 
the presence of transmitted drug resistance.
Methods
Data source and study population
Enrollment in the DC Cohort began in January 2011. 
Data on all consenting participants are electronically 
exported on a monthly basis. Historical data are manually 
abstracted including genotype and phenotype tests and 
date of ART initiation where available [38]. For the pre-
sent analysis, we included all active participants enrolled 
through December 2014 and not perinatally infected 
(n = 6506). Our study population included both recently 
infected individuals and people who had been living with 
HIV for many years. Participants with any documented 
genotype test between 1999 and 2014 were included for 
the estimates of CDR (n = 3411). Those who were docu-
mented treatment-naïve at first genotype test were evalu-
ated for TDR (n = 1503). Among the latter group, those 
who had one or more additional genotype tests after ART 
initiation were assessed for ADR (n = 309) (Fig. 1). The 
DC Cohort study was approved by the George Washing-
ton University Institutional Review Board (IRB), and all 
13 sites received IRB approval to participate in the study.
Measurement of resistance
Multiple commercial assays were used for the genotype 
testing, some of which occurred prior to study enroll-
ment. A total of 5993 genotypes were analyzed (Lab-
Corp: 3047; TruGene: 1279; Monogram Biosciences: 
621; Quest: 467; other: 579) representing all 13 clinical 
sites. Although major and minor mutations were avail-
able for the reverse transcriptase and protease genes, 
and sometimes for the envelope and integrase genes, full 
sequences were not available, and we did not have infor-
mation on which specific genotypes were evaluated for 
EI and INSTI resistance. We measured the prevalence 
of individual drug resistance mutations (DRMs) that 
were included in the WHO Surveillance Drug Resistance 
Mutations list [39] or in the 2014 International Antiviral 
Society-USA (IAS) HIV-1 drug mutations classification 
[40]. From the latter, we included all bolded amino acid 
substitutions and all mutations at bolded PI locations. 
We then interpreted resistance to drugs and drug classes 
using the IAS classification alone; however, for PIs, since 
the IAS guidelines identified only major locations and 
not specific amino acid substitutions, we used the 2014 
Stanford HIVDB genotypic resistance interpretation 
algorithm (Version 7.0), including intermediate and high-
level resistance mutations at bolded locations [41]. Phe-
notypic data were not examined.
To determine the prevalence of TDR, we used the 
first genotype test for each ART-naïve participant (1503 
tests). For ADR, we assessed mutations present in tests 
after ART initiation (557 tests) and absent in the initial 
test (309 tests). We did not have complete data on the 
drug regimen for each participant at the time of the test; 
therefore specific regimen was not taken into account. 
The CDR analysis group included all participants in the 
TDR and ADR groups as well as many more for whom we 
were not able to ascertain whether mutations were trans-
mitted or acquired. To estimate the prevalence of cumu-
lative drug resistance in this group, we included all DRMs 
on every test, regardless of treatment status at the time of 
testing (5993 tests). A participant with a given mutation 
on any test was considered to have that mutation for the 
remainder of the study period.
Analysis
Characteristics of the DC Cohort at enrollment were 
assessed as frequencies and proportions for categori-
cal variables and as medians and interquartile ranges for 
continuous variables. To evaluate trends in resistance 
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from 2004 to 2013, we used the Cochran–Armitage test 
with 2-sided p values. We performed simple and multi-
variable logistic regression to examine potential asso-
ciations between patient characteristics and transmitted 
resistance to any drug class. In the multivariable model, 
we included, a priori, age at genotype test, race/ethnicity, 
transmission risk group, and years from HIV diagnosis 
along with any variables that proved statistically signifi-
cant with α  =  0.05 in bivariate regression. All analysis 
was conducted using SAS 9.2 (SAS Institute, Cary, North 
Carolina).
Results
Demographics
The median age of DC Cohort participants at enrollment 
was 48  years. Participants were mostly male (73.8%), 
non-Hispanic black (76.4%) and infected through male-
to-male sex (38.7%) or heterosexual sex (30.7%). Nearly 
two-thirds had public health insurance (64.9%), and 
roughly equal numbers of participants received care at 
hospital-based clinics (48.2%) and community-based 
clinics (51.8%). Most participants had CD4 counts above 
500 cells/μl (51.5%) and viral loads below 400 copies/ml 
(75.7%) at enrollment; 41.6% of participants had been 
diagnosed with AIDS. The median interval between HIV 
diagnosis and consent date was 9.3 years (Table 1). Clini-
cal characteristics at enrollment were not reflected in the 
resistance results, which were based on genotype tests 
that were often performed years earlier or later.
Prevalence
Among the 5993 genotypes analyzed, 5895 were subtype 
B, 48 were C, 17 were AG, and 33 were other subtypes. 
In the TDR group (ART-naïve at genotype), prevalence 
of TDR to any drug class was 20.5%: 7.9% for NRTIs, 
11.7% for NNRTIs, 5.7% for PIs, 1.1% for EIs, and 0.9% 
for INSTIs (Table  2). In the ADR group (genotypes 
before and after ART initiation), ADR prevalence was 
40.5%; while in the CDR group (all participants tested), 
CDR prevalence was 45.1%. In terms of specific drugs, 
all three groups were most resistant to efavirenz (TDR: 
10.0%; ADR: 24.6%; CDR 27.2%), and nevirapine (TDR: 
10.2%; ADR: 23.9%; CDR 27.1%). The ADR and CDR 
groups also had high levels of resistance to emtricit-
abine and lamivudine (TDR: 3.1%; ADR: 20.4%; CDR: 
24.3%), and abacavir (TDR: 3.5%; ADR: 19.1%; CDR: 
Fig. 1 Composition of DC Cohort analysis groups, Washington DC, 1999–2014. CDR, cumulative drug resistance; TDR, transmitted drug resistance; 
ADR, acquired drug resistance; DRM, drug-resistant mutation; ART, antiretroviral therapy
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24.2%). Among the protease inhibitors, the highest levels 
of TDR and CDR were to nelfinavir (TDR: 1.9%; ADR: 
0.0%; CDR: 7.2%), and of ADR to atazanavir (TDR: 1.8; 
ADR: 3.2%; CDR: 5.3). No resistance to darunavir was 
detected as TDR, ADR, or CDR. Resistance to the fusion 
inhibitor enfuvirtide was found in a few participants 
(TDR: 1.1%; ADR: 1.0; CDR: 1.5). Maraviroc resistance 
was not assessed because tropism determination was 
not available. Mutations conferring resistance to ralte-
gravir (TDR: 0.6%; ADR: 1.6%; CDR: 1.5%) and elvite-
gravir (TDR: 0.9%; ADR: 0.6%; CDR: 1.3%) were found 
in all three analysis groups; while in the CDR group only, 
4 participants had evidence of resistance to dolutegravir 
(TDR: 0.0%; ADR: 0.0; CDR: 0.1%). Resistance to three 
or more classes was 1.2% for TDR, 1.9% for ADR, and 
7.1% for CDR.
The prevalence of the K103N mutation, associated 
with resistance to NNRTIs, was high for all three analy-
sis groups (TDR: 7.1%; ADR: 18.8%; CDR: 20.2%) (Fig. 2). 
Prevalence was also high for NRTI-associated mutations 
M41L (TDR: 3.0%; ADR: 1.0%; CDR: 7.3%) and M184V 
(TDR: 2.8%; ADR: 17.8%; CDR: 22.9%). Among protease-
associated mutations, L90M (TDR: 1.5%; ADR: 0.0%; 
CDR: 5.5%) was most prevalent in the TDR and CDR 
Table 1 Characteristics of DC Cohort at enrollment, Wash-
ington DC, 1999–2014
Characteristic at  enrollmenta N (%)
All participants 6506 (100)
Age
 <18 17 (0.26)
 18–29 693 (10.65)
 30–39 1134 (17.43)
 40–49 1945 (29.90)
 50–59 1948 (29.94)
 60+ 769 (11.82)
Sex
 Female 1702 (26.16)
 Male 4804 (73.84)
Race/ethnicity
 Non-Hispanic black 4972 (76.42)
 Non-Hispanic white 904 (13.89)
 Hispanic 282 (4.33)
 Other 127 (1.95)
 Unknown 221 (3.40)
Transmission risk group
 Male-to-male sexual contact (MMS) 2515 (38.66)
 Heterosexual contact 1995 (30.66)
 Injection drug use (IDU) 458 (7.04)
 MMS/IDU 80 (1.23)
 Other 121 (1.86)
 Unknown/missing 1337 (20.55)
Insurance
 Public 4222 (64.89)
 Private 1767 (27.16)
 Other 131 (2.01)
 Unknown 386 (5.93)
Clinic type
 Hospital-based 3136 (48.20)
 Community-based 3370 (51.80)
Clinical status
 HIV 3798 (58.38)
 AIDS 2708 (41.62)
CD4 count (cells/µl)
 <50 158 (2.43)
 50–199 525 (8.07)
 200–349 938 (14.42)
 350–499 1285 (19.75)
 ≥500 3349 (51.48)
 Unknown 251 (3.86)
Viral load (copies/ml)
 0–399 4922 (75.65)
 400–999 186 (2.86)
 1000–9999 366 (5.63)
 10,000–49,999 362 (5.56)
 50,000–99,999 155 (2.38)
 ≥100,000 250 (3.84)
Table 1 continued
Characteristic at  enrollmenta N (%)
 Unknown 265 (4.07)
Alcohol use
 Current 915 (14.06)
 Previous 924 (14.20)
 Never 3038 (46.70)
 Unknown 1629 (25.04)
Recreational drug use
 Current 774 (11.90)
 Previous 1416 (21.76)
 Never 2147 (33.00)
 Unknown 2169 (33.34)
Intravenous drug use
 Current 45 (0.69)
 Previous 476 (7.32)
 Never 3132 (48.14)
 Unknown 2853 (43.85)
Characteristic at  enrollmenta Median (IQR)
HIV diagnosis to consent (years) 9.3 (4.2–16.3)
HIV diagnosis to ART start (years) 1.2 (0.1–6.2)
ART start to consent (years) 3.6 (1.2–7.8)
ART, antiretroviral treatment
a Clinical characteristics at enrollment do not correspond to resistance results, 
which are based on tests performed at other times
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groups, and N88S (TDR: 1.3%; ADR: 2.6%; CDR: 2.6%) 
in the ADR group. Integrase-associated mutations were 
detected at nine sites: primarily at F121Y (TDR: 0.6%; 
ADR: 0.3%; CDR: 0.8%), E92Q (TDR: 0.3%; ADR: 0.3%; 
CDR: 0.2%), Q148R (TDR: 0.0%; ADR: 0.6%; CDR: 0.2%), 
and N155H (TDR: 0.0%; ADR: 0.0%; CDR: 0.2%). On the 
env gene, the most common mutation was N42T (TDR: 
0.3%; ADR: 0.0%; CDR: 0.6%).
Table 2 Prevalence of resistance to antiretroviral agents, Washington DC, 1999–2014
NRTI, nucleoside/nucleotide analogue reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; EI, entry/fusion 
inhibitor; INSTI, integrase strand transfer inhibitor
a Interpreted using 2014 International Antiviral Society-USA (IAS) HIV-1 drug mutations classification
b Interpreted using 2014 IAS classification and 2014 Stanford HIVDB genotypic resistance interpretation algorithm
c The 2014 IAS classification did not include maraviroc
Transmitted drug resistance
(n = 1503)
Acquired drug resistance
(n = 309)
Cumulative drug  
resistance
(n = 3411)
n % n % n %
NRTIsa
 Abacavir 52 3.5 59 19.1 826 24.2
 Didanosine 14 0.9 12 3.9 158 4.6
 Emtricitabine 47 3.1 63 20.4 828 24.3
 Lamivudine 47 3.1 63 20.4 828 24.3
 Stavudine 88 5.9 23 7.4 582 17.1
 Tenofovir 7 0.5 10 3.2 98 2.9
 Zidovudine 82 5.5 17 5.5 524 15.4
NNRTIsa
 Efavirenz 151 10.0 76 24.6 929 27.2
 Etravirine 19 1.3 11 3.6 212 6.2
 Nevirapine 153 10.2 74 23.9 926 27.1
 Rilpivirine 42 2.8 24 7.8 331 9.7
PIsb
 Atazanavir 27 1.8 10 3.2 181 5.3
 Darunavir 0 0.0 0 0.0 0 0.0
 Fosamprenavir 18 1.2 5 1.6 118 3.5
 Indinavir 17 1.1 2 0.6 175 5.1
 Lopinavir 22 1.5 4 1.3 166 4.9
 Nelfinavir 29 1.9 0 0.0 247 7.2
 Saquinavir 25 1.7 1 0.3 195 5.7
 Tipranavir 13 0.9 3 1.0 117 3.4
EIsa,c
 Enfuvirtide 17 1.1 3 1.0 52 1.5
INSTIsa
 Dolutegravir 0 0.0 0 0.0 4 0.1
 Elvitegravir 14 0.9 2 0.6 45 1.3
 Raltegravir 9 0.6 5 1.6 50 1.5
Any ARV 308 20.5 125 40.5 1538 45.1
Any NRTI 118 7.9 71 23.0 1013 29.7
Any NNRTI 176 11.7 81 26.2 998 29.3
Any PI 86 5.7 19 6.1 498 14.6
Any EI 17 1.1 3 1.0 52 1.5
Any INSTI 14 0.9 6 1.9 60 1.8
Any 2 classes 67 4.5 42 13.6 582 17.1
Any 3 classes 18 1.2 5 1.6 228 6.7
Any 4 classes 0 0.0 1 0.3 15 0.4
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Time trends
From 2004 to 2013, TDR was fairly stable around 20% 
(15.0–20.7%; p  =  0.76), with a marked decrease for 
NRTIs (15.0 to 5.5%; p =  0.0003) and a small increase 
for INSTIs (0.0–1.4%; p = 0.04) (Fig. 3). Over the same 
time period, the proportion of newly diagnosed par-
ticipants who had a genotype test within the first year 
of diagnosis steadily increased [5.5–65.9%; p  <  0.0001 
(data not shown)]. For ADR, the number of participants 
tested prior to 2008 was too small to permit meaning-
ful analysis (fewer than 10 per year). The prevalence of 
ADR decreased from 66.7% in 2008 to 41.6% in 2013 
(p = 0.003). ADR also decreased significantly for NRTIs 
(47.2 to 24.1%; p = 0.0004) and NNRTIs (47.2 to 26.9%; 
p  =  0.002). Resistance to PIs rose slightly (5.6–6.3%; 
p  =  0.25), but the difference was not significant and 
as noted above, no resistance was found to daruna-
vir, which has perhaps the highest barrier to resistance. 
CDR prevalence to any drug class declined significantly 
from 70.6% in 2004 to 45.0% in 2013 (p  <  0.0001). The 
trend was also significant for NRTIs (63.9 to 29.9%; 
p  <  0.0001), NNRTIs (43.6 to 29.1%; p  <  0.0001), PIs 
(32.4 to 14.8%; p < 0.0001), and to any 2 (33.6 to 17.0%; 
p < 0.0001) or 3 (17.9 to 6.9%; p < 0.0001) drug classes, 
while resistance increased for EIs (0.0–1.5%; p < 0.0001), 
INSTIs (0.0–1.8%; p < 0.0001), and any four drug classes 
(0.0–0.4%; p < 0.0001).
Logistic regression analysis
We decided a priori to include age at test, race/ethnic-
ity, transmission risk group and years from HIV diag-
nosis in the multivariable regression model. Based on a 
statistically significant association at the α =  0.05 level 
in bivariate regression analysis, we added clinic type to 
the model. In multivariable analysis, TDR was not pre-
dicted by time between HIV diagnosis and genotype, age 
at genotype or race/ethnicity. Although not statistically 
significant, individuals infected through injection drug 
use (OR 1.53; 95% CI 0.79–2.97) and those receiving 
HIV care at community-based clinics (OR 1.27; 95% CI 
0.95–1.72) were more likely to have transmitted resist-
ance than individuals infected through male-to-male 
Fig. 2 Most prevalent drug-resistant mutations for each analysis group by drug class, Washington DC, 1999–2014. NRTI, nucleoside/nucleotide 
analogue reverse transcriptase inhibitor (top 4); NNRTI, nonnucleoside reverse transcriptase inhibitor (top 4); PI, protease inhibitor (top 4); EI, entry/
fusion inhibitor (top 2); INSTI, integrase strand transfer inhibitor (top 2)
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sexual contact and participants cared for at hospital-
based clinics, respectively.
Discussion
To our knowledge, we are the first to report positive find-
ings of mutations associated with transmitted resistance 
to INSTIs (0.9%) and EIs (1.1%). We also found evidence 
of resistance to these classes among participants analyzed 
for ADR and CDR as well as significantly increasing trends 
for cumulative resistance to both classes and transmit-
ted resistance to INSTIs. Unfortunately we were not able 
to determine which genotypes included the INSTI and EI 
encoding regions, and so we report prevalence among all 
genotypes assessed; thus, our rates are underestimates of 
prevalence for these classes. The emergence of resistance 
to INSTIs is likely due to their increasingly widespread 
use in clinical practice as well as their earlier use in clinical 
trials. Several DC sites participated in registration trials 
for all three INSTIs, the first of which (raltegravir) was 
FDA-approved in 2007; and by the end of 2014, approxi-
mately 10% of DC Cohort participants were on INSTI-
based regimens. Surprisingly, resistance to elvitegravir—as 
interpreted using the IAS guidelines—was higher than to 
raltegravir, although the latter was introduced earlier. This 
was mainly attributable to the presence of E92Q and T66I 
mutations. In the most recent US Department of Health 
and Human Services (DHHS) treatment guidelines, four 
of the five recommended regimens for ART-naïve patients 
were INSTI-based, while inclusion of the integrase region 
in routine genotype testing was still optional [31]. Given 
the emergence of INSTI resistance in the Washington, DC 
area, baseline resistance testing for integrase inhibitors 
should be strongly considered.
The TDR prevalence of 20.5% found in this analysis was 
comparable to rates reported throughout the US and in 
Washington, DC. We were surprised to find that 18 par-
ticipants analyzed for TDR had mutations associated with 
resistance to three drug classes. Review of the medical 
records for these 18 participants is warranted to confirm 
that the recorded dates are accurate. Our findings of no 
significant association between TDR and sex, race/eth-
nicity, or transmission risk group support those of most 
[11, 14, 21, 28], but not all [10] previous studies. However, 
resistance appeared to be higher among injection drug 
users (IDUs), and although the difference was of border-
line significance, it is plausible given that IDUs may have 
more barriers to adherence and retention in care [42].
Cumulative drug resistance may serve as a measure of a 
community’s burden of ARV resistance and, like commu-
nity viral load, may reflect the success of treatment and 
adherence in that community [43]; however, these results 
should be interpreted with caution. First, the decrease 
in CDR observed between 2006 and 2010 was probably 
due in part to the dilution effect of increased resistance 
testing among newly diagnosed individuals following the 
2007 DHHS recommendations [31]. Second, because 
patients on treatment generally have genotype testing 
performed when treatment fails, the prevalence of resist-
ance in tested individuals may be higher than in the over-
all population of persons infected with HIV. To avoid 
this overestimation of resistance, others have included 
all treatment-experienced patients in the denomina-
tor [44] or used modeling to extend resistance estimates 
from tested to untested individuals [45]. By assuming 
that untested individuals do not have resistance, the 
former approach underestimates prevalence. Using this 
method, we found that resistance appeared to increase as 
the proportion of participants tested increased dramati-
cally over the time period (results not shown). That is, 
the degree of underestimation decreased over time, and 
Fig. 3 Trends in antiretroviral resistance by drug class, Washington 
DC, 2004–2013. TDR, transmitted drug resistance; ADR, acquired drug 
resistance; CDR, cumulative drug resistance. Results for 2014 are not 
shown due to incomplete data at the time of analysis
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the resulting apparent increase in resistance was mis-
leading. In future analysis, we hope to model resistance 
in the overall Cohort taking into account the rate of test-
ing and other secular trends. Third, our measurements 
were based on genotype tests that do not detect minor-
ity or archived HIV strains and thus, may underestimate 
the true prevalence of resistance. Furthermore, some 
transmitted archived strains may not have been detected 
until after treatment was initiated, resulting in misclas-
sification of TDR as ADR. However, since our estimates 
for ADR and CDR were cumulative, we maximized our 
ability to include archived strains within the limitations 
of the tests.
Other strengths of this study include the large size and 
representative, citywide composition of the DC Cohort, 
together with the availability of genotypic, demographic, 
and clinical data. The long-term use of INSTIs in the 
study population provided early evidence of resistance 
to this drug class, while the longitudinal data allowed us 
to assess acquired and cumulative resistance in a large 
cohort.
Conclusions
In this urban cohort of HIV-infected persons in care, 
almost half of participants tested had evidence of CDR, 
and resistance to INSTIs was increasing. If this trend 
continues, inclusion of the integrase-encoding region in 
routine genotype testing may become advisable. With 
new treatment guidelines recommending immediate ini-
tiation of ART for most people, innovations to promote 
adherence, such as co-formulations and longer-acting 
regimens, will be more critical than ever. Continued close 
surveillance of transmitted and acquired resistance will 
measure the success of these efforts and inform future 
testing and treatment guidelines.
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